Current report
Open the filing on sec.gov
Acumen Pharmaceuticals, Inc. (ABOS)
Nasdaq: ABOS · Biological Products, (No Diagnostic Substances) · Newton, MA · filing with the SEC since 2013
The companyfiscal 2025, as filed
Revenuen/a
Net income-$121M-18.6%
Earnings per share$-2.00-17.0%
Operating cash flow-$116M-34.0%
Cash$54.0M+51.5%
Debt$22.4M-23.9%
Shareholders’ equity$70.4M-61.3%
Shares, diluted60.6M+0.9%
Return on equity-172.3%
The recordfrom its filings
Filings in 2026111
Newest filingNov 5 · 8-K
Annual reportMar 26, 2026
Quarterly reportOct 26, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$600,000
Insider buys, 12 months$0.00
Patents granted8
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$104MCash from operations -$88.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Draft registration, confidential
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.